Early-Onset Colorectal Cancer Shows a Distinct Molecular Profile: ESMO GI Oncology |September 2026

Introduction:

Early-onset colorectal cancer (EOCRC) is rising globally and increasingly appears to be biologically distinct from conventional later-onset CRC. This large clinicogenomic analysis evaluated 6,762 tumors across four age groups, showing that mutation patterns change substantially with age and may carry implications for prognosis, molecular testing, and treatment selection.

Why was this study needed?

EOCRC is increasing despite declining CRC incidence in older adults.

Younger patients often present with more advanced and aggressive disease.

Standard molecular testing may not fully capture age-specific biology.

Defining age-related genomic differences could reveal actionable therapeutic targets.

Results:

APC mutations increased progressively with age: 49.4% at 18–29 years versus 75.3% at ≥50 years.

SMAD4 mutations were enriched in the youngest patients: 31.6% at 18–29 years versus approximately 17–19% in older groups.

POLE mutations peaked at age 30–39 years (10.7%), nearly twice the frequency seen in patients over 40.

Overall, 22 genes showed significant age-related variation, supporting a noncanonical genomic landscape in EOCRC.

Clinical Impact:

The enrichment of POLE mutations is particularly important because pathogenic POLE proofreading-domain alterations can generate an ultramutated, highly immunogenic tumor phenotype and may predict substantial benefit from immune checkpoint inhibition.

The lower frequency of canonical APC alterations and higher SMAD4 prevalence in very young patients also support the concept that EOCRC may follow different tumorigenic pathways, rather than simply representing conventional CRC occurring earlier.

These findings strengthen the case for broad molecular profiling in young patients, alongside universal mismatch-repair/MSI testing and appropriate germline assessment.

Bottom Line:

Early-onset colorectal cancer is not simply “colorectal cancer in a younger patient.” Its genomic landscape differs by age, with fewer APC mutations, greater SMAD4 enrichment in the youngest patients, and a striking POLE signal in those aged 30–39 years. Expanded molecular profiling may uncover clinically actionable biology and improve precision treatment in EOCRC.